natgillin/translations-raw huggingface dataset:
Studies in mice and rats showed developmental effects (see section 5.3).
Študije na miših in podganah so pokazale učinke na razvoj (glejte poglavje 5.3).
• statins such as pitavastatin, rosuvastatin (used to lower blood cholesterol)
• statine, kot sta pitavastatin, rosuvastatin (za zniževanje ravni holesterola v krvi).
It belongs to a group of medicines called “oxazolidinones”.
Spada v skupino zdravil, ki jih imenujemo "oksazolidinoni".
• sumatriptan, zolmitriptan (used to treat migraine)
• sumatriptan, zolmitriptan (za zdravljenje migrene)
It is used to treat adults with infections of the skin and tissues below the skin.
Uporablja se za zdravljenje odraslih z okužbami kože in mehkih tkiv.
Membrane transporters
Membranski prenašalci
Appropriate supportive measures, antibiotic treatment of C. difficile, and surgical evaluation should be considered.
Razmisliti je treba tudi o ustreznih podpornih ukrepih, zdravljenju okužbe s C. difficile z antibiotiki in kirurški oceni.
In such cases, prompt evaluation is recommended with referral to an ophthalmologist as necessary.
V teh primerih se priporoča takojšnja ocena stanja in po potrebi napotitev k oftalmologu.
Tedizolid phosphate film-coated tablets or powder for concentrate for solution for infusion may be used as initial therapy.
Tedizolid fosfat v obliki filmsko obloženih tablet ali praška za koncentrat za raztopino za infundiranje se lahko uporabi za začetno zdravljenje.
• Blurred vision, ‘floaters' (small shapes seen floating in the field of vision)
• zamegljen vid, "motnjave" v očesu (majhne oblike, ki lebdijo v vidnem polju)
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
Potrebna je natančna anamneza, saj so o pojavu CDAD poročali v obdobju več kot dveh mesecev po uporabi antibiotikov.
Adverse reactions are classified by preferred term and System Organ Class, and by frequency.
Neželeni učinki so razvrščeni po priporočenih izrazih, organskih sistemih in pogostnosti.
Shaking or rapid movement should be avoided as it may cause foaming.
Tresenju ali hitrim gibom se je treba izogibati, ker lahko povzročijo penjenje.
If CDAD is suspected or confirmed, tedizolid phosphate and, if possible, other antibacterial agents not directed against C. difficile should be discontinued and adequate therapeutic measures should be initiated immediately.
V primeru suma ali potrditve CDAD je treba prekiniti uporabo tedizolid fosfata in če je mogoče drugih antibiotikov, ki niso usmerjeni proti C. difficile, ter nemudoma uvesti ustrezne terapevtske ukrepe.
The impact of gender on the pharmacokinetics of tedizolid phosphate was evaluated in healthy males and females in clinical studies and in a population pharmacokinetics analysis.
Vpliv spola na farmakokinetiko tedizolid fosfata so ocenili pri zdravih moških in ženskah v kliničnih študijah in populacijskih farmakokinetičnih analizah.
The most commonly observed mutations in staphylococci and enterococci that result in oxazolidinone resistance are in one or more copies of the 23S rRNA genes (G2576U and T2500A).
Najpogosteje opažene mutacije pri stafilokokih in enterokokih, ki povzročajo odpornost na oksazolidinone, so v eni ali več kopijah genov 23S rRNA (G2576U in T2500A).
EU/1/15/991/002 1 vial EU/1/15/991/003 6 vials
EU/1/15/991/002 1 viala EU/1/15/991/003 6 vial
No meaningful changes in blood pressure or heart rate with pseudoephedrine were observed in the healthy volunteers, and no clinically relevant increase in tyramine sensitivity was observed.
Opazili niso ne pomembnih sprememb krvnega tlaka ali srčnega utripa pri uporabi psevdoefedrina pri zdravih prostovoljcih ne klinično pomembnega povečanja občutljivosti za tiramin.
Film-coated tablet 6 x 1 film-coated tablets
filmsko obložene tablete 6 x 1 filmsko obložena tableta
Do not use Lactated Ringer's Injection or Hartmann's Solution.
Ne uporabljajte raztopine Ringerjevega laktata za injiciranje ali Hartmannove raztopine.
The powder will be reconstituted in the vial with 4 mL of water for injections.
Prašek se rekonstituira v viali s 4 ml vode za injekcije.
If the same intravenous line is used for sequential infusion of several different medicinal products, the line should be flushed before and after infusion with 0.9% sodium chloride.
Če se za zaporedno infundiranje več različnih zdravil uporabi ista intravenska linija, je treba pred infuzijo in po njej linijo sprati z 0,9-odstotno raztopino natrijevega klorida.
• imatinib, lapatinib (used to treat cancer)
• imatinib, lapatinib (za zdravljenje raka)
Due to a hydroxymethyl group in the C5 position, tedizolid retains activity against strains of Staphylococcus aureus that express the cfr gene in the absence of chromosomal mutations.
Zaradi hidroksimetilne skupine v položaju C5 je pri tedizolidu ohranjena aktivnost proti sevom Staphylococcus aureus, ki izražajo gen cfr v odsotnosti kromosomskih mutacij.
Animal studies with tedizolid phosphate do not indicate harmful effects with respect to fertility (see section 5.3).
Študije na živalih s tedizolid fosfatom niso pokazale škodljivih učinkov na plodnost (glejte poglavje 5.3).
Sivextro vials are intended for single use only.
Viale z zdravilom Sivextro so samo za enkratno uporabo.
Antibacterial activity in combination with other antibacterial and antifungal agents
Protibakterijsko delovanje v kombinaciji z drugimi antibiotiki in antimikotiki
Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Pogostnosti neželenih učinkov so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
Frequencies are defined as: very common (≥1/10); common (≥ 1/100 to < 1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare
Pogostnosti neželenih učinkov so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki
Tedizolid phosphate should be administered with caution in patients known to be hypersensitive to other oxazolidinones since cross-hypersensitivity may occur.
Tedizolid fosfat je treba uporabljati previdno pri bolnikih z znano preobčutljivostjo na druge oksazolidinone, saj lahko pride do navzkrižne preobčutljivosti.
Do not use this medicine after the expiry date which is stated on the vial label after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki viale poleg oznake "EXP".
The recommended dose is one 200 mg tablet once a day for 6 days.
Priporočeni odmerek je ena 200 mg tableta enkrat dnevno 6 dni.
The European Medicines Agency has deferred the obligation to submit the results of studies with Sivextro in one or more subsets of the paediatric population in the treatment of acute bacterial skin and skin structure infections (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Sivextro za eno ali več podskupin pediatrične populacije, zdravljenih zaradi akutnih bakterijskih okužb kože in mehkih tkiv (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Less than 3% of tedizolid phosphate administered dose is excreted as active tedizolid.
Manj kot 3 % uporabljenega odmerka tedizolid fosfata se izloči v obliki aktivnega tedizolida.
Antibacterial activity against other relevant pathogens
Protibakterijska aktivnost proti drugim pomembnim patogenom
Beta haemolytic streptococci of Groups A,B,C,G Viridans group streptococci (Streptococcus anginosus group only)
Betahemolitični streptokoki skupin A, B, C, G Streptokoki skupine Viridans (samo skupina Streptococcus anginosus)
Prescribing tedizolid phosphate in the absence of a proven or strongly suspected bacterial infection increases the risk of the development of drug-resistant bacteria.
Predpisovanje tedizolid fosfata brez dokazane bakterijske okužbe ali utemeljenega suma nanjo poveča tveganje za razvoj bakterij, odpornih na zdravila.
When incubated with pooled human liver microsomes, tedizolid was stable suggesting that tedizolid is not a substrate for hepatic CYP450 enzymes.
Pri inkubaciji z združenimi človeškimi jetrnimi mikrosomi je bil tedizolid stabilen, kar nakazuje, da tedizolid ni substrat za jetrne encime citokroma CYP450.
Sivextro must be administered by intravenous infusion over a 60-minute period.
Zdravilo Sivextro je treba aplicirati v intravenski infuziji v 60 minutah.
Controlled clinical studies did not include patients with neutropenia (neutrophil counts <1,000 cells/mm
V nadzorovane klinične študije niso bili vključeni bolniki z nevtropenijo (število nevtrofilcev < 1.000 celic/mm
Aseptic technique must be followed when preparing the infusion solution.
Pri pripravi raztopine za infundiranje je treba uporabiti aseptično tehniko.
Organisms resistant to oxazolidinones via mutations in chromosomal genes encoding 23S rRNA or ribosomal proteins (L3 and L4) are generally cross-resistant to tedizolid.
Organizmi, ki so odporni na oksazolidinon zaradi mutacij v kromosomskih genih, ki kodirajo 23S rRNA ali ribosomske beljakovine (L3 in L4), so običajno navzkrižno odporni na tedizolid.
Tedizolid is a reversible, non-selective inhibitor of monoamine oxidase (MAO) in vitro (see section 4.5).
Tedizolid je reverzibilen, neselektiven zaviralec monoaminooksidaze (MAO) in vitro (glejte poglavje 4.5).
Long-term carcinogenicity studies have not been conducted with tedizolid phosphate.
Dolgotrajne študije kancerogenosti s tedizolid fosfatom niso bile opravljene.
It will be given to you through a drip directly into a vein (intravenously) over approximately 1 hour.
Zdravilo boste prejeli v obliki infuzije v veno (intravensko), ki bo trajala približno 1 uro.
Recommended dose and duration The recommended dosage is 200 mg once daily for 6 days.
Priporočeni odmerek in trajanje zdravljenja Priporočeni odmerek je 200 mg enkrat dnevno 6 dni.
It is not known if Sivextro passes into breast milk in humans.
Ni znano, ali zdravilo Sivextro prehaja v materino mleko.
mannitol, sodium hydroxide, hydrochloric acid
manitol, natrijev hidroksid, klorovodikova kislina
For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6
Za navodila glede rekonstitucije in redčenja zdravila pred dajanjem glejte poglavje 6.6.
These findings suggest a higher frequency of infusion related reactions (phlebitis) than was observed in previous clinical studies with tedizolid phosphate.
Te ugotovitve kažejo na večjo pogostnost pojava reakcije na mestu infundiranja (flebitis), kot je bila opažena v prejšnjih kliničnih študijah s tedizolid fosfatom.
• Anxiety, irritability, shaking or trembling
• tesnoba, razdražljivost, tresenje ali drgetanje
In vitro studies in human liver microsomes indicate that tedizolid phosphate and tedizolid do not significantly inhibit metabolism mediated by any of the following CYP isoenzymes (CYP1A2, CYP2C19, CYP2A6, CYP2C8, CYP2C9, CYP2D6, and CYP3A4).
Študije in vitro na človeških jetrnih mikrosomih kažejo, da tedizolid fosfat in tedizolid bistveno ne zavirata presnove preko katerega koli od naslednjih izoencimov CYP (CYP1A2, CYP2C19, CYP2A6, CYP2C8, CYP2C9, CYP2D6 in CYP3A4).
• topotecan (used to treat cancer)
• topotekan (za zdravljenje raka)
In cases where tedizolid phosphate was discontinued, the affected haematological parameters have returned back to pre-treatment levels.
V primerih, ko so zdravljenje s tedizolid fosfatom opustili, so se spremenjeni hematološki parametri povrnili na enake vrednosti, kot so bile pred zdravljenjem.
Sivextro is administered intravenously over approximately 1 hour.
Zdravilo Sivextro se aplicira intravensko približno eno uro.
The safety profile in this study was similar to the Phase 3 clinical trials; however, infusion site reactions (phlebitis) were reported more frequently (2.7%) in tedizolid phosphate treated subjects than in the linezolid control group (0%), particularly among Asian patients.
Varnostni profil v študiji je bil podoben kot v kliničnih preskušanjih 3. faze, vendar je bila reakcija na mestu infundiranja (flebitis) poročana pogosteje pri bolnikih, zdravljenih s tedizolid fosfatom (2,7 %), kot pri bolnikih, zdravljenih z linezolidom (0 %), še posebej pri bolnikih azijskega porekla.
The film coat of the tablet contains polyvinyl alcohol, titanium dioxide (E171), macrogol, talc and yellow iron oxide (E172).
Filmska obloga tablete vsebuje polivinilalkohol, titanov dioksid (E171), makrogol, smukec in rumeni železov oksid (E172).
Table 1 Frequency of adverse reactions by System Organ Class in comparative clinical studies
Preglednica 1 Pogostnost neželenih učinkov po organskih sistemih v primerjalnih kliničnih študijah
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially “sodiumfree.”
Zdravilo Sivextro vsebuje natrij To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni 'brez natrija'.
Potential serotonergic interactions
Možne serotoninergične interakcije
• Decrease or loss of skin sensitivity, tingling/prickling skin sensation
• zmanjšanje ali izguba občutljivosti kože, mravljinčenje/zbadajoč občutek na koži
The effects of tedizolid phosphate on fertility in humans have not been studied.
Učinkov tedizolid fosfata na plodnost pri ljudeh niso raziskovali.
Laboratoires Merck Sharp & Dohme-Chibret Route de Marsat, Riom 63963, Clermont-Ferrand Cedex 9 France
Laboratoires Merck Sharp & Dohme-Chibret Route de Marsat, Riom 63963, Clermont-Ferrand Cedex 9 Francija
The safety and efficacy of tedizolid phosphate when administered for periods longer than 6 days have not been established (see section 4.4).
Varnost in učinkovitost tedizolid fosfata pri uporabi, daljši od 6 dni, nista bili dokazani (glejte poglavje 4.4).
Patients who commence treatment on the parenteral formulation may be switched to the oral presentation when clinically indicated.
Bolniki, ki so začeli zdravljenje s parenteralno obliko zdravila, lahko preidejo na peroralno obliko, kadar je to klinično indicirano.
• Swelling in ankles and/or feet
• zatečeni gležnji in/ali stopala
The AUC/MIC ratio was the pharmacodynamic parameter shown to best correlate with efficacy in mouse thigh and lung S. aureus infection models.
Razmerje AUC/MIK je farmakodinamični parameter, ki najbolje korelira z učinkovitostjo pri mišjih modelih okužbe stegna in pljuč z bakterijo S. aureus.
Oval (13.8 mm long by 7.4 mm wide) yellow film-coated tablet debossed with “TZD” on the obverse side and “200” on the reverse side.
Ovalne (13,8 mm dolge in 7,4 mm široke) rumene filmsko obložene tablete z vtisnjenima oznakama "TZD" na eni in "200" na drugi strani.
• The other ingredients are microcrystalline cellulose, mannitol, povidone, crospovidone and magnesium stearate within the tablet core.
• Druge sestavine zdravila so mikrokristalna celuloza, manitol, povidon, krospovidon in magnezijev stearat v jedru tablete.
What Sivextro looks like and contents of the pack Sivextro is an oval, yellow film-coated tablet imprinted with ‘TZD' on one side and ‘200' on the other side.
Izgled zdravila Sivextro in vsebina pakiranja Zdravilo Sivextro je v obliki ovalnih, rumenih filmsko obloženih tablet z vtisnjenima oznakama "TZD" na eni in "200" na drugi strani.
imipramine, isocarboxazid, lofepramine, moclobemide, paroxetine, phenelzine, selegiline and sertraline (used to treat depression)
izokarboksazid, lofepramin, moklobemid, paroksetin, fenelzin, selegilin in sertralin (za zdravljenje depresije)
Only limited data are available on the compatibility of Sivextro with other intravenous substances, therefore additives or other medicinal products should not be added to Sivextro single use vials or infused simultaneously.
Ker je podatkov o kompatibilnosti zdravila Sivextro z drugimi intravenskimi učinkovinami malo, se vialam zdravila Sivextro za enkratno uporabo ne sme dodati aditivov ali drugih zdravil in se jih ne sme infundirati sočasno.
The time to tedizolid peak concentration with oral administration under fasting conditions is 6 hours faster than when administered with a high-fat, high-calorie meal (see section 5.2).
Čas do najvišje koncentracije tedizolida pri peroralni uporabi na tešče je za 6 ur krajši kot pri zaužitju z visokokaloričnim obrokom z visoko vsebnostjo maščob (glejte poglavje 5.2).
In an animal model of infection, the antibacterial activity of tedizolid was reduced in the absence of granulocytes.
Pri živalskem modelu okužbe se je protibakterijsko delovanje tedizolida v odsotnosti granulocitov zmanjšalo.
There are no data from the use of tedizolid phosphate in pregnant women.
Podatkov o uporabi tedizolid fosfata pri nosečnicah ni.
Haemodialysis does not result in meaningful removal of tedizolid from systemic circulation.
Hemodializa ne odstrani pomembne količine tedizolida iz sistemskega obtoka.
You should take all 6 tablets to complete your course of treatment, even if you have missed a dose.
Tudi če ste izpustili odmerek, morate vzeti vseh 6 tablet, da dokončate zdravljenje.
Multiple sulfotransferase (SULT) isoforms (SULT1A1, SULT1A2, and SULT2A1) were identified in vitro that are capable of conjugating tedizolid which suggests that no single isozyme is critical to the clearance of tedizolid.
In vitro so opredelili več izooblik sulfotransferaze (SULT) (SULT1A1, SULT1A2 in SULT2A1), ki so sposobne konjugacije tedizolida, kar nakazuje, da za očistek tedizolida ni ključen noben posamezen izoencim.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before using this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali medicinsko sestro, preden prejmete to zdravilo.
Insomnia Sleep disorder Anxiety Nightmare
Psihiatrične motnje nespečnost motnje spanja anksioznost nočne more
Effects of Sivextro on other medicines
Vplivi zdravila Sivextro na druga zdravila
The most frequently reported adverse reactions occurring in patients receiving tedizolid phosphate in the pooled controlled Phase 3 clinical studies (tedizolid phosphate 200 mg once daily for 6 days) were nausea (6.9%), headache (3.5%), diarrhoea (3.2%) and vomiting (2.3%), and were generally mild to moderate in severity.
Najpogosteje poročani neželeni učinki v združenih nadzorovanih kliničnih študijah 3. faze pri bolnikih, ki so prejemali tedizolid fosfat (200 mg tedizolid fosfata enkrat dnevno 6 dni), so bili navzea (6,9 %), glavobol (3,5 %), diareja (3,2 %) in bruhanje (2,3%) ter so bili večinoma blagi do zmerni.
It is unknown whether tedizolid phosphate or its metabolites are excreted in human milk.
Ni znano, ali se tedizolid fosfat in njegovi presnovki izločajo v materino mleko.
, Mg including Lactated Ringer's Injection and Hartmann's Solution.
, Mg vključno z raztopino Ringerjevega laktata za injiciranje in Hartmannovo raztopino.
Peripheral neuropathy and optic nerve disorders
Periferna nevropatija in motnje očesnega živca
In vitro studies have shown that drug interactions between tedizolid and inhibitors or inducers of cytochrome P450 (CYP) isoenzymes are unanticipated.
Študije in vitro so pokazale, da medsebojnega delovanja tedizolida in zaviralcev ali induktorjev izoencimov citokroma P450 (CYP) ni pričakovati.
There is limited experience with tedizolid phosphate in the treatment of patients with concomitant acute bacterial skin and skin structure infections and secondary bacteremia and no experience in the treatment of ABSSSI with severe sepsis or septic shock.
S tedizolid fosfatom je malo izkušenj pri zdravljenju bolnikov s sočasnimi akutnimi bakterijskimi okužbami kože in mehkih tkiv ter sekundarno bakteriemijo ter nobenih izkušenj pri zdravljenju akutnih bakterijskih okužb kože in mehkih tkiv s hudo sepso ali septičnim šokom.
Your doctor will decide if you should be given Sivextro to treat your infection.
Zdravnik bo presodil, ali je zdravilo Sivextro primerno za zdravljenje vaše okužbe.
CDAD may range in severity from mild diarrhoea to fatal colitis.
Resnost CDAD lahko sega od blage diareje do kolitisa s smrtnim izidom.
The median tyramine dose required to cause an increase in systolic blood pressure of ≥30 mmHg from pre-dose baseline was 325 mg with tedizolid phosphate compared to 425 mg with placebo.
Mediani odmerek tiramina, potreben za povzročitev zvišanja sistoličnega krvnega tlaka za ≥ 30 mmHg glede na izhodiščno vrednost pred odmerkom, je bil pri tedizolid fosfatu 325 mg in pri placebu 425 mg.
Tedizolid inhibits mitochondrial protein synthesis.
Tedizolid zavira sintezo mitohondrijskih beljakovin.
Tedizolid did not alter activity of selected CYP isoenzymes, but induction of CYP3A4 mRNA was observed in vitro in hepatocytes.
Tedizolid ni spremenil aktivnosti izbranih izoencimov CYP, vendar so in vitro opazili indukcijo CYP3A4 mRNA v hepatocitih.
• Infusion reactions (chills, shaking or shivering with fever, muscle pain, swelling of the face, weakness, fainting, shortness of breath, chest tightness and angina pectoris).
• reakcije na infuzijo (mrazenje, tresenje ali drgetanje z zvišano telesno temperaturo, bolečine v mišicah, zatečen obraz, šibkost, omedlevica, zasoplost, tiščanje v prsih in angina pektoris)
In vitro drug combination studies with tedizolid and amphotericin B, aztreonam, ceftazidime, ceftriaxone, ciprofloxacin, clindamycin, colistin, daptomycin, gentamicin, imipenem, ketoconazole, minocycline, piperacillin, rifampicin, terbinafine, trimethoprim/sulfamethoxazole, and vancomycin indicate that neither synergy nor antagonism have been demonstrated.
Študije kombinacij zdravil in vitro, opravljene s tedizolidom in amfotericinom B, aztreonamom, ceftazidimom, ceftriaksonom, ciprofloksacinom, klindamicinom, kolistinom, daptomicinom, gentamicinom, imipenemom, ketokonazolom, minociklinom, piperacilinom, rifampicinom, terbinafinom, trimetoprimom/sulfametoksazolom ter vankomicinom, niso pokazale niti sinergije niti antagonizma.
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
The pharmacokinetics of tedizolid were similar in males and females.
Farmakokinetika tedizolida je bila pri moških in ženskah podobna.
If you forget to take Sivextro
Če ste pozabili vzeti zdravilo Sivextro
As a precautionary measure, it is preferable to avoid the use of tedizolid phosphate during pregnancy.
Iz previdnostnih razlogov se je med nosečnostjo uporabi tedizolid fosfata bolje izogibati.
Neuropathy (optic and peripheral) has not been reported in patients treated with tedizolid phosphate at the recommended treatment duration of 6 days.
O nevropatiji (optični in periferni) niso poročali pri bolnikih, ki so se zdravili s tedizolid fosfatom v priporočenem obdobju 6 dni.
• The active substance is tedizolid phosphate.
• Učinkovina je tedizolid fosfat.
Grip strength decreased Transaminases increased White blood cell count decreased
Preiskave šibkejši prijem zvišane ravni transaminaz zmanjšanje števila belih krvnih celic
• The other ingredients are mannitol, sodium hydroxide (for pH adjustment) and hydrochloric acid (for pH adjustment).
• Druge sestavine zdravila so manitol, natrijev hidroksid (za uravnavanje pH) in klorovodikova kislina (za uravnavanje pH).
The resulting solution is a clear colourless or light-yellow solution.
Pripravljena raztopina je bistra in brezbarvna ali svetlo rumena.
Efficacy has been demonstrated in clinical studies against the pathogens listed under each indication that were susceptible to tedizolid in vitro.
V kliničnih študijah je bila dokazana učinkovitost proti patogenom, ki so našteti pri posamezni indikaciji in so bili in vitro občutljivi za tedizolid.
No meaningful changes in blood pressure or heart rate were seen with pseudoephedrine.
Pri psevdoefedrinu niso opazili pomembnih sprememb krvnega tlaka ali srčnega utripa.
You will be given one 200 mg infusion of Sivextro once a day for 6 days.
Eno infuzijo z 200 mg odmerkom zdravila Sivextro boste enkrat dnevno prejemali 6 dni.